Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Article in Neurology and Therapy (March 2024)
The most recent citing publications are shown below. View all 12 publications that cite this research output on Dimensions.
The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness
Article in Neurological Sciences (March 2024)
Factors Associated with Patient Adherence to Biofeedback Therapy Referral for Migraine: An Observational Study
Article in Applied Psychophysiology and Biofeedback (February 2024)